Researchers confirm the safety of Oxford-AstraZeneca COVID-19 vaccine
Category: #headlines |   By Hrishikesh Kadam |   Date: 2020-12-10

Researchers confirm the safety of Oxford-AstraZeneca COVID-19 vaccine

Researchers have reportedly confirmed the safety and efficacy of the Oxford/AstraZeneca COVID-19 vaccine in a study published in the Lancet journal. Even though most people in the study were aged less than 55, it has been found that the vaccine works well in older people as well. The vaccine is further speculated to assist in the reduction of the spread of COVID-19 as well as in offering protection against the disease and death.

According to AstraZeneca’s CEO, Pascal Soriot, the results of the study demonstrate the effectiveness of the vaccine against COVID-19, with no hospitalizations and no severe infections found in the vaccine group. Soriot has further highlighted that with the vaccine being well tolerated and safe, the company has begun the submission of data to regulatory authorities across the world for obtaining early approval.

The company’s worldwide supply chains are up and running, all set for the quick commencement of the delivery of hundreds of millions of doses at no profit at the global level, added the CEO.

Out of thousands of people involved in the trial, around 1,367 people were given the half dose followed by a full dose, which provided them with 90 per cent protection against falling ill with COVID-19. The presence of a comparatively small number in this group, however, signifies that it is difficult to draw firm conclusions as none of the members of the group were above 55 and experts know that it is older people who are the most vulnerable to severe SARS-CoV-2 illness.

Expressing his opinion over the publication of the study, Wellcome’s Head of Vaccines, Dr. Charlie Weller, mentioned that the study marks another significant milestone in the COVID-19 journey. Weller further stated that, even though Wellcome awaits full data and trial completion, it is extremely encouraging to witness that the data behind the interim results, announced in the previous month, comprised an analysis of the various dosing regimens. This suggests the capability of the vaccine to prevent the spread of the asymptomatic disease, added Weller.

Source credit: https://www.bbc.com/news/health-55228422

  • shareShare
  • Twitter
  • Facebook
  • LinkedIn


About Author

Hrishikesh Kadam     Twitter

Hrishikesh Kadam

A graduate in electronics and telecommunication engineering, Hrishikesh Kadam has always found writing fascinating. Driven by a never-ending passion for content creation combined with a bit of experience in writing personal blogs, Hrishikesh blends his technical knowl Read more...

More News By Hrishikesh Kadam

Cloud solution provider Cloopen to acquire Zhuge in cash & stock deal

Cloud solution provider Cloopen to acquire Zhuge in cash & stock deal

By Hrishikesh Kadam

Cloopen Group Holding Limited, one of China’s leading multi-capability cloud-based communications solution providers, has announced that it has made a definitive agreement to purchase complete equity interests in Zhuge Inc., a provider of user-...

Sense raises USD 90 Mn in Series D to expand its HR tech offerings

Sense raises USD 90 Mn in Series D to expand its HR tech offerings

By Hrishikesh Kadam

HR tech firm Sense has multiplied its valuation to USD 500 million in its 50 million Series D fundraise, spearheaded by SoftBank Vision Fund. The five-and-a-half-year-old San Francisco-based startup, which caters to blue-collar workers and assists co...

Mazda Australia faces heat over misleading customers seeking refunds

Mazda Australia faces heat over misleading customers seeking refunds

By Hrishikesh Kadam

The court identified Mazda made 49 distinct fraudulent or misleading representations to nine consumers who sought a refund or replacement of their cars. Australian Competition and Consumer Commission (ACCC) initially filed the case against Mazda, ...